RT Journal Article
T1 The administration of atomoxetine during alcohol deprivation induces a time-limited increase in alcohol consumption after relapse.
A1 Alén, Francisco
A1 Serrano, Antonia
A1 Gorriti, Miguel Ángel
A1 Pavón, Francisco Javier
A1 Orio, Laura
A1 Gómez de Heras, Raquel
A1 Ramírez-López, María Teresa
A1 Antón, María
A1 Pozo, Miguel Ángel
A1 Rodríguez de Fonseca, Fernando
K1 Alcoholism
K1 Atomoxetine
K1 Rat
K1 Relapse
K1 Antidepressants
K1 Consumo de alcohol
K1 Depresores del sistema nervioso central
K1 Modelos de enfermedad en animales
K1 Etanol
K1 Inhibidores de la captación adrenérgica
AB The administration of selective serotonin reuptake inhibitors (SSRIs) typically used as antidepressants increases alcohol consumption after an alcohol deprivation period in rats. However, the appearance of this effect after the treatment with selective noradrenaline reuptake inhibitors (SNRIs) has not been studied. In the present work we examined the effects of a 15-d treatment with the SNRI atomoxetine (1, 3 and 10 mg/kg, i.p.) in male rats trained to drink alcohol solutions in a 4-bottle choice test. The treatment with atomoxetine (10 mg/kg, i.p.) during an alcohol deprivation period increased alcohol consumption after relapse. This effect only lasted one week, disappearing thereafter. Treatment with atomoxetine did not cause a behavioral sensitized response to a challenge dose of amphetamine (1.5 mg/kg, i.p.), indicating the absence of a supersensitive dopaminergic transmission. This effect is markedly different from that of SSRI antidepressants that produced both long-lasting increases in alcohol consumption and behavioral sensitization. Clinical implications are discussed.
PB Oxford University Press
SN 1461-1457
YR 2014
FD 2014-11
LK http://hdl.handle.net/10668/1981
UL http://hdl.handle.net/10668/1981
LA en
NO Alén F, Serrano A, Gorriti MÁ, Pavón FJ, Orio L, de Heras RG, et al. The administration of atomoxetine during alcohol deprivation induces a time-limited increase in alcohol consumption after relapse. Int. J. Neuropsychopharmacol. 2014; 17(11):1905-10
NO Journal Article; Research Support, Non-U.S. Gov't;
DS RISalud
RD Apr 17, 2025